Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia.
Rev Bras Hematol Hemoter
; 33(2): 131-9, 2011.
Article
em En
| MEDLINE
| ID: mdl-23284261
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Rev Bras Hematol Hemoter
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Brasil